Billing and Coding: MolDX: BCR-ABL

This MolDX billing/coding policy (effective 2013-04-15) directs that BCR-ABL1 breakpoint panels or NGS translocation analyses assigned a single test ID be billed using CPT 81479, with NGS and certain mutation tests requiring one UOS and the assigned DEX Z-code. FDA-approved MRDx BCR-ABL is billed with CPT 0040U; ABL1 kinase domain mutation analysis for imatinib resistance is billed with CPT 81170 (one UOS with DEX Z-code); CPT 81206/81207/81208 are allowed only when reported as a single test or per the panel reporting rules.

"When BCR-ABL1 breakpoint testing is performed as a combination/panel of major, minor, or other breakpoints (multiple tests assigned a single ID), report CPT 81479."

Sign up to see full coverage criteria, indications, and limitations.